Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.

MLA

Dong, Liang, et al. “Inhibition of Glycosphingolipid Synthesis with Eliglustat in Combination with Immune Checkpoint Inhibitors in Advanced Cancers: Preclinical Evidence and Phase I Clinical Trial.” Nature Communications, vol. 15, no. 1, Aug. 2024, pp. 1–19. EBSCOhost, https://doi.org/10.1038/s41467-024-51495-3.

APA

Dong, L., Cao, Z., Chen, M., Liu, Y., Ma, X., Lu, Y., Zhang, Y., Feng, K., Zhang, Y., Meng, Z., Yang, Q., Wang, Y., Wu, Z., & Han, W. (2024). Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nature Communications, 15(1), 1–19. https://doi.org/10.1038/s41467-024-51495-3

Chicago

Dong, Liang, Zhi Cao, Meixia Chen, Yang Liu, Xinran Ma, Yuting Lu, Yan Zhang, et al. 2024. “Inhibition of Glycosphingolipid Synthesis with Eliglustat in Combination with Immune Checkpoint Inhibitors in Advanced Cancers: Preclinical Evidence and Phase I Clinical Trial.” Nature Communications 15 (1): 1–19. doi:10.1038/s41467-024-51495-3.